Joseph P. Hagan

President, Chief Executive Officer, Chief Financial Officer & Director at Regulus Therapeutics, Inc.

Joseph P. Hagan

Joseph P. Hagan

President, Chief Executive Officer, Chief Financial Officer & Director at Regulus Therapeutics, Inc.

Overview
Career Highlights

Orexigen Therapeutics, Inc.
Regulus Therapeutics, Inc.
Unity Pharma

RelSci Relationships

1967

Number of Boards

9

Birthday

1969

Age

50

Relationships
RelSci Relationships are individuals Joseph P. Hagan likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at SENTÉ, Inc. (California)

Relationship likelihood: Strong

Founding President & Chief Executive Officer at Codiak Biosciences, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Coda Biotherapeutics, Inc.

Relationship likelihood: Strong

President Emeritus at California Institute of Technology

Relationship likelihood: Strong

Director at Grail, Inc.

Relationship likelihood: Strong

Co-Founder at Exelixis, Inc.

Relationship likelihood: Strong

Founder at PWH Advisors

Relationship likelihood: Strong

Chief Financial Officer & Executive Vice President at Tocagen, Inc.

Relationship likelihood: Strong

Chief Executive Officer at ZP Opco, Inc.

Relationship likelihood: Strong

Co-Founder at Blackthorn Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Joseph P. Hagan
Potential Connections via
Relationship Science
You
Joseph P. Hagan
President, Chief Executive Officer, Chief Financial Officer & Director at Regulus Therapeutics, Inc.
Education
B.S. in Physiology & Neuroscience

The University of California, San Diego (also referred to as UC San Diego or UCSD) is a public research university located in La Jolla, California, United States. Established in 1960 near the pre-existing Scripps Institution of Oceanography, UCSD is the seventh oldest of the 10 University of California campuses and offers over 200 undergraduate and graduate degree programs. UCSD is one of America's Public Ivy universities, which recognizes top public research universities in the United States.

M.B.A.

The Northeastern University D'Amore-McKim School of Business was founded in 1922 and the Graduate School of Business Administration in 1952. The D'Amore-McKim School of Business is accredited by AACSB International-The Association to Advance Collegiate Schools of Business. The Co-op M.B.A. program matriculates a class of about 80 students each fall and spring. A typical entering class includes students from fifteen or more countries other than the United States. Career goals can be equally diverse. About 90 percent have work experience, and 65 percent have earned their undergraduate degrees in areas other than business.

Career History
President, Chief Executive Officer, Chief Financial Officer & Director
2016 - Current

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Director
Prior - 2009

Accelerator Corp. invests in emerging life sciences opportunities. Through the global activities of their affiliates, the firm has access to new technologies and commercial opportunities developed at leading research institutions, universities and biotechnology companies around the world. Accelerator Corp. looks for companies that are milestone-driven and have a set of objectives designed to advance novel technologies rapidly from discovery to a proof-of-concept development stage that supports further financing.

Chief Financial Officer
2009 - 2015

Mr. Keyes joined Orexigen in January 2013 as its Vice President of Finance. Prior to joining Orexigen, Mr. Keyes was at Amylin Pharmaceuticals, Inc. as Senior Director of Finance from May 2012 to January 2013 and Director, Manufacturing, Operations and Quality Finance from August 2007 to May 2012. Previously, he worked in financial and corporate strategy at Amgen, Inc. from March 2004 to July 2007, and at Baxter Healthcare Corporation from July 2002 to March 2004. Mr. Keyes holders a B.S. and M.S. in Civil Engineering from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Boards & Committees
Director
Prior - 2007

Avidia, Inc. developed pharmaceutical products. The company developed a novel, proprietary class of small therapeutic proteins. The company was headquartered in Mountain View, CA.

Director
Prior

Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company.Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California.

Member, Board of Directors
Prior

Seredigm Corp. develops and supplies drugs that protect against tissue damage in acute and chronic medical conditions. The company was founded by John M. Harlan and Robert K. Winn in 2006 and is headquartered in Seattle, WA

Political Donations
$1,000
2012

Former Representative from California's 50th Congressional District

Transactions
Details Hidden

Regulus Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Orexigen Therapeutics, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Joseph P. Hagan. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Joseph P. Hagan's profile does not indicate a business or promotional relationship of any kind between RelSci and Joseph P. Hagan.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/joseph-p-hagan-3546403
  • https://relationshipscience.com/person/joseph-p-hagan-3546403